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Sir: A 38-year-old woman (gravida 2,
para 3) was referred to our hospital
because of intractable postpartum
hemorrhagic shock. During this
gemelli pregnancy she was admitted
to the hospital three times for vaginal
blood loss. Ultrasonography revealed
a hematoma and a placenta close
to the cervical ostium. Coagulation
and platelets were normal. Because
of fetal distress during spontaneous
labor at 34 weeks an emergency
Fig.1 Right foot of the patient
cesarean section was performed.
Vaginal hemorrhage began after
abdominal closure. Management
consisted of uterotonic drugs, in-
travenous ﬂuids, red blood cells,
and fresh frozen plasma without ef-
fect. Supravaginal hysterectomy was
deemed necessary. Because of pelvic
oozing the abdomen was closed after
packing of the pelvis. She was still
in hemorrhagic shock. Recombinant
human activated factor VIIa (rFVIIa;
NovoSeven) was administered twice
as a 7.2-mg intravenous bolus at an
interval of 120min, but bleeding
continued from almost all oriﬁces.
The next day she was referred.
Hemodynamic instability persisted,
and multiorgan failure developed.
Angiography of the pelvic arteries
resulted in coiling of three small
arteries, but hemostasis was not
achieved. On the third day tranexamic
acid was added and, after lack of
effect, a 9-mg intravenous bolus
of rFVIIa (90µg/kg). Coagulation
parameters improved and for several
hours the hemoglobin level was
stable, but she developed blistering
of arms, ﬁngers, and feet with slow
capillary reﬁll. Toes, heel, and sole
of the right foot became black and
cold. On laparotomy packings and
9l blood and cloths were removed.
Afterwards there was no bleeding.
The ischemia worsened in a few
days and spread to the fore foot
(Fig. 1) resulting in amputation of
the lower extremity. Necrosis also
developed on the dorsal side of the
left fore arm. Other acra were cyan-
otic but did not become necrotic.
Since delivery she had received 48U
red blood cells, 30U fresh frozen
plasma and 17U ﬁve donors each
of platelets. Multiorgan failure im-
proved, and 19days after admission
the patient was discharged to the
ward.
rFVIIa use has been reported for
severe postpartum hemorrhage [1, 2].
Immediately after administration of
the third dose of rFVIIa hemostasis
was indeed reached. However, severe
thromboembolic complications oc-
curred. Although there seems to be
a relationship in time between the
onset of complications and moment
of drug administration, it is hard
to conﬁrm this relationship. rFVIIa
overdosing or sepsis may also play
a role. However, there was no positive
conﬁrmation of infection.
The incidence of thrombotic
complications in licensed use is
1–2%. Most thromboembolic events
have followed off-label use of
rFVIIa [3]. Off-label rFVIIa is used
principally in desperate situations.
However, to make a balanced choice,
even then we need to have an im-
pression of the complication rate.
Safety and efﬁcacy in off-label use
must be studied [4]. Pregnant and
postpartum women should receive
special attention in these studies be-
cause of their particular coagulation
condition.212
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